Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX

Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months

· Issued by Vertex Pharmaceuticals Incorporated via Business Wire

On 6ix: 6ix.com/news/vertex-announces-us-fda-approval-for-orkambir-lumacaftor-ivacaftor-in-children-with

Watch Vertex Pharmaceuticals' latest callVertex Pharmaceuticals (NASDAQ:VRTX) Q2 2026 Earnings Call · Replay · Aug 3Read the transcript of Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2026 Earnings Call
Vertex Pharmaceuticals' next earnings callVertex Pharmaceuticals (NASDAQ:VRTX) Q3 2026 Earnings Call · Nov 2, 2026 at 4:30 PM ESTRegister

-With this approval, approximately 300 children with two copies of the F508del mutation will have a medicine to treat the underlying cause of their disease for the first time-

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved expanded use of ORKAMBI® (lumacaftor/ivacaftor) to include children with cystic fibrosis (CF) ages 12 to

Vertex Pharmaceuticals Incorporated on 6ix

Story so far

Earlier from Vertex Pharmaceuticals

Later from Vertex Pharmaceuticals

All Vertex Pharmaceuticals news releases